Metastatic Spinal Cord CompressionRESONATENCT06965101
To Determine Whether it is Feasible to Treat Patients Requiring Urgent Radiotherapy Diagnosed With Metastatic Cord Compression (MSCC) on the Magnetic Resonance Linear Accelerator (MRL) in a Single Appointment and Compare it to the Standard of Care Radiotherapy Pathway
A study testing Radiotherapy to the spine in a single appointment in people with Metastatic Spinal Cord Compression, run by The Christie NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
The goal of this clinical trial is to understand whether the Magnetic Resonance Linear Accelerator (MRL) could expedite Radiotherapy treatment for Metastatic Cord Compression (MSCC) by removing the need for a planning CT (pCT) scan prior to treatment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Metastatic Spinal Cord Compression
- What is being tested?
- Radiotherapy to the spine in a single appointment
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 72 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 4 Nov 2025to 4 Nov 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Confirmed Diagnosis of MSCC
- Referred for an 8Gy, Single Fraction of Radiotherapy
- 18 years or older.
- Able to give informed consent in writing or verbally.
- Willing to complete patient experience questionnaire
- Willing to have the research team review their case notes for up to 1 year following
Who cannot join
- Participant does not have capacity and cannot give informed consent.
- Any evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator, make it undesirable for the patient to participate in the study.
- Participant is unwilling to allow researchers to access their clinical notes and diagnostic scans.
- Participant is unwilling to complete an experience questionnaire
- The participant cannot speak or understand English.
- Any contraindications to MRI identified after MRI safety screening
Show all 10Show fewer
- Unable to tolerate MRI scanning
- Uncontrolled pain/ poor pain control.
- MSCC in the cervical spine.
- More than one vertebral level of compression
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
The Christie NHS Foundation Trust
Manchester, M20 4BX
Cynthia L Eccles, +447590992488, cynthia.eccles1@nhs.net
Research Radiographer, the-christie.radiotherapyclinicaltrials@nhs.net
About this study
Official title: Rapid Response MRI-Guided Palliative Radiotherapy
The goal of this clinical trial is to understand whether the Magnetic Resonance Linear Accelerator (MRL) could expedite Radiotherapy treatment for Metastatic Cord Compression (MSCC) by removing the need for a planning CT (pCT) scan prior to treatment. Radiotherapy will be delivered in one appointment on the MRL and compared to the standard of care of two appointments: a CT scan and a Radiotherapy appointment.
The main questions it aims to answer are:
Read more
- Can the MRL deliver successful treatment of MSCC in a single 1-hour appointment?
- Can the MRL treat participants within 24 hours from the doctor's decision to treat?
- Did it take less time from consent to completion of treatment when patients were treated on the MRL?
- Do the questionnaire scores reflect satisfaction with treatment on the MRL? Researchers will compare treatment on the MRL in one appointment to a group receiving standard of care radiotherapy in two appointments.
Participants in both groups will receive the same prescription of 8Gray (Gy) in one treatment (fraction) delivered with one posterior-anterior beam as per our department policies and national standards.
Participants will be asked to complete an optional questionnaire prior to treatment to monitor the diversity of the study population. This questionnaire is anonymised, no personal data that could identify a participant is collected on this questionnaire.
After treatment participants will be asked to complete an experience questionnaire, to assess treatment experience.
Once the questionnaire is complete active participation in the trial is no longer needed, researchers will monitor participants notes for up to 12 months after treatment to record participant well being and function.
Read the detailed description
Metastatic cord compression occurs in 5-10% of patients with cancer often affected the ends stages of a patient's illness. The benefit of palliation is directly related to the speed of treatment, National Institute of Health and Care Excellence (NICE) guidelines recommend that radiotherapy is given within 24 hours of a decision to treat. A recent audit of the current referrals and pathway showed the average time from consultation to treatment is 2.10 days (SD 12.2 days). This audit concluded the need to improve the speed of access to care.
The current pathway includes a scan for diagnosis (MRI), a visit for a planning CT and time to plan the treatment before treatment delivery. This can take many hours or even days. To provide quicker access to care it is intended to use the MR Linac with an integrated adaptive radiotherapy platform, to deliver a scan, plan and treat model in a single appointment.
Preliminary work has modelled dose differences due to the presence of a magnetic field, known as the electron return effect and developed an MR only workflow using a simple planning technique to enable the online scan, plan and treat model.
The primary objective is to test the feasibility of a one-stop MR guided palliative radiotherapy programme for patients with MSCC.
Secondary objectives are:
- To reduce overall time from decision to treat to treatment delivery.
- Reduce the number of appointments and procedure required to provide palliative radiotherapy for patients with MSCC.
- Compare participant experience of MSCC treatment on the MR Linac to the current standard of care pathway.
This is a single centre, non-randomised clinical trial. All patients referred for radiotherapy to treat MSCC who can provide informed consent can be considered. Participants will be asked to have treatment on the MR Linac within a single appointment and complete an experience questionnaire. If participants would not like to have treatment on the MRL or do not meet the inclusion criteria participants can continue the standard of care pathway with the addition of completing an experience questionnaire and the data and answers will be used for analysis. If patients would not like to participate, standard of care radiotherapy will be delivered and this patient data will not be used for this study.
The study is expected to recruit up to 72 participants over a 2-year period using a 1:2 ratio. Up to 24 participants will be recruited to the MR Linac Arm of the study. This sample is based on resource constraints, the MR Linac can accommodate one patient per month on average. Recruitment will be a 1:2 ratio to reduce bias to the investigational arm.
To test the aim, to improve the speed of access of care, timings will be collected at certain time points throughout the pathway:
- Clinical decision to treat the participant
- Time of treatment consent
- Time of Radiotherapy Planning scan (Standard of Care only)
- Time of Radiotherapy Completion
The study will consist of:
- MSCC team confirm diagnosis \& organise for the patient to be transferred to the Christie. (Day 0)
- Referral to Radiotherapy (Day 0)
- Approached in person by the Research Team \& MRI screening. (Day 1)
- Consent to Radiotherapy. (Day 1)
- Consent to Study. (Day 1)
- Optional Equality diversity and inclusivity (EDI) Questionnaire completed. (Day1)
- Patient prepared in MRL clinical system or given RTP appointment. (Day 1)
- Radiotherapy treatment on MRL or Conventional Linac. (Day 1 -7)
- Patient experience questionnaire completed. (Same day as treatment)
- Patient outcomes will be determined from clinical notes. (1,3,6,12 months following treatment)
A participant is free to withdraw from the clinical trial at any point without giving a reason.
This study will run for 3 years in total, 2 years for recruitment plus one year for follow up unless early termination is required.
- Conditions
- Metastatic Spinal Cord Compression
- Being tested
- Radiotherapy to the spine in a single appointment
- Keywords
- Radiotherapy, MR Linac, MSCC, CT Sim Free, One Stop, MR Guided
- Medical subject headings
- Spinal Cord Compression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Radiotherapy to the spine in a single appointmentRadiation
8Gy/ 1# to be delivered to all participants using a single posterior direct field.
| Study group | Role | What they receive |
|---|---|---|
| MRL | Active comparator | Using the MR Linac to deliver Radiotherapy in a single treatment without the need for a prior planning CT scan. Receives: Radiation: Radiotherapy to the spine in a single appointment |
| Standard of Care | Placebo comparator | Using a conventional linear accelerator to deliver Radiotherapy in a single treatment, participants will require a prior planning CT appointment before Radiotherapy can be delivered. Receives: Radiation: Radiotherapy to the spine in a single appointment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Successful treatment of Metastatic Spinal Cord Compression in a single 1 hour appointment for 80% of patients on the MRL Arm
"Successful treatment" is defined as the complete delivery of the Radiotherapy treatment beam to the area of Metastatic Spinal Cord Compression.
The measurement used to assess appointment length will be time, recorded in hours, minutes and seconds. Time from the patient entering the room to the treatment beam completing.
Measured: The event is assessed on a single day (within 24hours) over a single appointment. From the time the patient enters the treatment room to the time the radiotherapy beam is completed (Up to 2 hours in length).
Secondary outcomes (4)
80% of patients on the MRL Arm treated within 24 hours from decision to treat
The measurement used to assess will be the length of time (in days, hours, minutes). Assessed from the time the Radiotherapy referral form is submitted by the clinician to when the Radiotherapy treatment beam is completed.
Measured: From clinician's referral to the completion of the treatment beam (Assessed for up to 7 days).
80% of patients on the MRL Arm spend less time from consent to completion of treatment when compared to the Standard of Care Arm
The measurement used to assess will be the length of time (in days, hours, minutes). Assessed from the time the Radiotherapy treatment consent form is signed by the participant to when the Radiotherapy treatment beam is completed.
Measured: From time of treatment consent to completion of the treatment beam (Assessed for up to 7 days)
80% of the MRL Arm questionnaire scores reflect satisfaction with the treatment
The experience questionnaire collects answers on a 4-point Likert scale from 0-3. "Satisfaction" is defined as scores that are above 1 for positive questions, those that high scores indicate a positive experience. Or scores that are below 2 for negative questions, those that high scores indicate a negative experience.
Measured: After completion of Radiotherapy (Within 2 hours of the treatment beam being completed)
The study population is representative of the population referred for Radiotherapy for Metastatic Spinal Cord Compression.
Voluntary questionnaire completed. Equality Diversity and Inclusion (EDI) data from this study will be compared to local and national EDI data statistics for MSCC patients. The percentage of characteristics represented in the study compared to the wider population.
Measured: At the time of enrolment (within 2 hours of signing consent form)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2025
- Study start4 Nov 2025
- Primary completion4 Nov 2027 (estimated)
- Study completion4 Nov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Metastatic Spinal Cord CompressionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Non Randomised, single centre study design. Participants will choose, if they meet all eligibility criteria, which treatment group they would like to participate in. Either to receive Radiotherapy on the MR Linac or standard of care Radiotherapy. If participants do not meet the eligibility criteria and would like to participate they will be assigned to the standard of care Radiotherapy group.
- Masking
- None (open label)
- Enrolment
- 72 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Christie NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Cynthia L Eccles, Principal investigator, The Christie NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06965101
- Sponsor's protocol ID
- CFTSp246
- Acronym
- RESONATE
- Status last verified
- Nov 2025
- First submitted
- 11 Apr 2025
- Last updated
- 2 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data for this study will be pseudo-anonymised and kept securely at The Christie, only accessible to those employed by the Christie NHS Foundation Trust. Due to the data not being fully anonymised and to preserve patient confidentiality the data from this study will not be shared.
Publications
Olausson K, Holst Hansson A, Zackrisson B, Edvardsson D, Ostlund U, Nyholm T. Development and psychometric testing of an instrument to measure the patient's experience of external radiotherapy: The Radiotherapy Experience Questionnaire (RTEQ). Tech Innov Patient Support Radiat Oncol. 2017 Jul 24;3-4:7-12. doi: 10.1016/j.tipsro.2017.06.003. eCollection 2017 Sep-Dec.
PubMed 32095560Barnes H, Alexander S, Bower L, Ehlers J, Gani C, Herbert T, Lawes R, Moller PK, Morgan T, Nowee ME, Smith G, van Triest B, Tyagi N, Whiteside L, McNair H. Development and results of a patient-reported treatment experience questionnaire on a 1.5 T MR-Linac. Clin Transl Radiat Oncol. 2021 Jun 29;30:31-37. doi: 10.1016/j.ctro.2021.06.003. eCollection 2021 Sep.
PubMed 34307911Hales RB, Rodgers J, Whiteside L, McDaid L, Berresford J, Budgell G, Choudhury A, Eccles CL. Therapeutic Radiographers at the Helm: Moving Towards Radiographer-Led MR-Guided Radiotherapy. J Med Imaging Radiat Sci. 2020 Sep;51(3):364-372. doi: 10.1016/j.jmir.2020.05.001. Epub 2020 Jun 26.
PubMed 32600981Benson R, Clough A, Nelder C, Pitt E, Portner R, Vassiliou M, McDaid L, Choudhury A, Rembielak A, Eccles C. Evaluation of the palliative radiotherapy pathway in a single institute: Can an MR Linac improve efficiency? J Med Imaging Radiat Sci. 2022 Jun;53(2 Suppl):S44-S50. doi: 10.1016/j.jmir.2021.11.010. Epub 2021 Dec 16.
PubMed 34922879
Study at a glance
From the registry record, last updated by the sponsor on 2 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Rapid Response MRI-Guided Palliative Radiotherapy
- ClinicalTrials.gov ID
- NCT06965101
- Acronym / sponsor ID
- RESONATE / CFTSp246
- Conditions
- Metastatic Spinal Cord Compression
- Keywords
- Radiotherapy, MR Linac, MSCC, CT Sim Free, One Stop, MR Guided
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 72 participants (estimated)
- Lead sponsor
- The Christie NHS Foundation TrustUniversity, hospital or other
- Study start
- 4 Nov 2025 (actual)
- Primary completion
- 4 Nov 2027 (estimated)
- Study completion
- 4 Nov 2028 (estimated)
- First posted
- 11 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to understand whether the Magnetic Resonance Linear Accelerator (MRL) could expedite Radiotherapy treatment for Metastatic Cord Compression (MSCC) by removing the need for a planning CT (pCT) scan prior to treatment. Radiotherapy will be delivered in one appointment on the MRL and compared to the standard of care of two appointments: a CT scan and a Radiotherapy appointment.
The main questions it aims to answer are:
- Can the MRL deliver successful treatment of MSCC in a single 1-hour appointment?
- Can the MRL treat participants within 24 hours from the doctor's decision to treat?
- Did it take less time from consent to completion of treatment when patients were treated on the MRL?
- Do the questionnaire scores reflect satisfaction with treatment on the MRL? Researchers will compare treatment on the MRL in one appointment to a group receiving standard of care radiotherapy in two appointments.
Participants in both groups will receive the same prescription of 8Gray (Gy) in one treatment (fraction) delivered with one posterior-anterior beam as per our department policies and national standards.
Participants will be asked to complete an optional questionnaire prior to treatment to monitor the diversity of the study population. This questionnaire is anonymised, no personal data that could identify a participant is collected on this questionnaire.
After treatment participants will be asked to complete an experience questionnaire, to assess treatment experience.
Once the questionnaire is complete active participation in the trial is no longer needed, researchers will monitor participants notes for up to 12 months after treatment to record participant well being and function.
Detailed description
Metastatic cord compression occurs in 5-10% of patients with cancer often affected the ends stages of a patient's illness. The benefit of palliation is directly related to the speed of treatment, National Institute of Health and Care Excellence (NICE) guidelines recommend that radiotherapy is given within 24 hours of a decision to treat. A recent audit of the current referrals and pathway showed the average time from consultation to treatment is 2.10 days (SD 12.2 days). This audit concluded the need to improve the speed of access to care.
The current pathway includes a scan for diagnosis (MRI), a visit for a planning CT and time to plan the treatment before treatment delivery. This can take many hours or even days. To provide quicker access to care it is intended to use the MR Linac with an integrated adaptive radiotherapy platform, to deliver a scan, plan and treat model in a single appointment.
Preliminary work has modelled dose differences due to the presence of a magnetic field, known as the electron return effect and developed an MR only workflow using a simple planning technique to enable the online scan, plan and treat model.
The primary objective is to test the feasibility of a one-stop MR guided palliative radiotherapy programme for patients with MSCC.
Secondary objectives are:
- To reduce overall time from decision to treat to treatment delivery.
- Reduce the number of appointments and procedure required to provide palliative radiotherapy for patients with MSCC.
- Compare participant experience of MSCC treatment on the MR Linac to the current standard of care pathway.
This is a single centre, non-randomised clinical trial. All patients referred for radiotherapy to treat MSCC who can provide informed consent can be considered. Participants will be asked to have treatment on the MR Linac within a single appointment and complete an experience questionnaire. If participants would not like to have treatment on the MRL or do not meet the inclusion criteria participants can continue the standard of care pathway with the addition of completing an experience questionnaire and the data and answers will be used for analysis. If patients would not like to participate, standard of care radiotherapy will be delivered and this patient data will not be used for this study.
The study is expected to recruit up to 72 participants over a 2-year period using a 1:2 ratio. Up to 24 participants will be recruited to the MR Linac Arm of the study. This sample is based on resource constraints, the MR Linac can accommodate one patient per month on average. Recruitment will be a 1:2 ratio to reduce bias to the investigational arm.
To test the aim, to improve the speed of access of care, timings will be collected at certain time points throughout the pathway:
- Clinical decision to treat the participant
- Time of treatment consent
- Time of Radiotherapy Planning scan (Standard of Care only)
- Time of Radiotherapy Completion
The study will consist of:
- MSCC team confirm diagnosis \& organise for the patient to be transferred to the Christie. (Day 0)
- Referral to Radiotherapy (Day 0)
- Approached in person by the Research Team \& MRI screening. (Day 1)
- Consent to Radiotherapy. (Day 1)
- Consent to Study. (Day 1)
- Optional Equality diversity and inclusivity (EDI) Questionnaire completed. (Day1)
- Patient prepared in MRL clinical system or given RTP appointment. (Day 1)
- Radiotherapy treatment on MRL or Conventional Linac. (Day 1 -7)
- Patient experience questionnaire completed. (Same day as treatment)
- Patient outcomes will be determined from clinical notes. (1,3,6,12 months following treatment)
A participant is free to withdraw from the clinical trial at any point without giving a reason.
This study will run for 3 years in total, 2 years for recruitment plus one year for follow up unless early termination is required.
Study design
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Non Randomised, single centre study design. Participants will choose, if they meet all eligibility criteria, which treatment group they would like to participate in. Either to receive Radiotherapy on the MR Linac or standard of care Radiotherapy. If participants do not meet the eligibility criteria and would like to participate they will be assigned to the standard of care Radiotherapy group.
| Arm | Type | Receives |
|---|---|---|
| MRL | Active comparator | Radiation: Radiotherapy to the spine in a single appointmentUsing the MR Linac to deliver Radiotherapy in a single treatment without the need for a prior planning CT scan. |
| Standard of Care | Placebo comparator | Radiation: Radiotherapy to the spine in a single appointmentUsing a conventional linear accelerator to deliver Radiotherapy in a single treatment, participants will require a prior planning CT appointment before Radiotherapy can be delivered. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Confirmed Diagnosis of MSCC
- Referred for an 8Gy, Single Fraction of Radiotherapy
- 18 years or older.
- Able to give informed consent in writing or verbally.
- Willing to complete patient experience questionnaire
Key exclusion criteria (10 listed)
- Participant does not have capacity and cannot give informed consent.
- Any evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator, make it undesirable for the patient to participate in the study.
- Participant is unwilling to allow researchers to access their clinical notes and diagnostic scans.
- Participant is unwilling to complete an experience questionnaire
- The participant cannot speak or understand English.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Radiotherapy to the spine in a single appointment8Gy/ 1# to be delivered to all participants using a single posterior direct field. | Radiation | MRL, Standard of Care |
Primary outcome
Successful treatment of Metastatic Spinal Cord Compression in a single 1 hour appointment for 80% of patients on the MRL Arm
Time frame: The event is assessed on a single day (within 24hours) over a single appointment. From the time the patient enters the treatment room to the time the radiotherapy beam is completed (Up to 2 hours in length).
"Successful treatment" is defined as the complete delivery of the Radiotherapy treatment beam to the area of Metastatic Spinal Cord Compression. The measurement used to assess appointment length will be time, recorded in hours, minutes and seconds. Time from the patient entering the room to the treatment beam completing.
4 secondary outcomes
80% of patients on the MRL Arm treated within 24 hours from decision to treat
Time frame: From clinician's referral to the completion of the treatment beam (Assessed for up to 7 days).
80% of patients on the MRL Arm spend less time from consent to completion of treatment when compared to the Standard of Care Arm
Time frame: From time of treatment consent to completion of the treatment beam (Assessed for up to 7 days)
80% of the MRL Arm questionnaire scores reflect satisfaction with the treatment
Time frame: After completion of Radiotherapy (Within 2 hours of the treatment beam being completed)
The study population is representative of the population referred for Radiotherapy for Metastatic Spinal Cord Compression.
Time frame: At the time of enrolment (within 2 hours of signing consent form)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Dec 2025.
- Background: PubMed 32095560Olausson K, Holst Hansson A, Zackrisson B, Edvardsson D, Ostlund U, Nyholm T. Development and psychometric testing of an instrument to measure the patient's experience of external radiotherapy: The Radiotherapy Experience Questionnaire (RTEQ). Tech Innov Patient Support Radiat Oncol. 2017 Jul 24;3-4:7-12. doi: 10.1016/j.tipsro.2017.06.003. eCollection 2017 Sep-Dec.
- Background: PubMed 34307911Barnes H, Alexander S, Bower L, Ehlers J, Gani C, Herbert T, Lawes R, Moller PK, Morgan T, Nowee ME, Smith G, van Triest B, Tyagi N, Whiteside L, McNair H. Development and results of a patient-reported treatment experience questionnaire on a 1.5 T MR-Linac. Clin Transl Radiat Oncol. 2021 Jun 29;30:31-37. doi: 10.1016/j.ctro.2021.06.003. eCollection 2021 Sep.
- Background: PubMed 32600981Hales RB, Rodgers J, Whiteside L, McDaid L, Berresford J, Budgell G, Choudhury A, Eccles CL. Therapeutic Radiographers at the Helm: Moving Towards Radiographer-Led MR-Guided Radiotherapy. J Med Imaging Radiat Sci. 2020 Sep;51(3):364-372. doi: 10.1016/j.jmir.2020.05.001. Epub 2020 Jun 26.
- Background: PubMed 34922879Benson R, Clough A, Nelder C, Pitt E, Portner R, Vassiliou M, McDaid L, Choudhury A, Rembielak A, Eccles C. Evaluation of the palliative radiotherapy pathway in a single institute: Can an MR Linac improve efficiency? J Med Imaging Radiat Sci. 2022 Jun;53(2 Suppl):S44-S50. doi: 10.1016/j.jmir.2021.11.010. Epub 2021 Dec 16.
- NICE Guideline NG234 - Spinal Metastasis and Metastatic Spinal Cord CompressionLink provided by the sponsor.
- Individual participant dataSharing planned: No. Data for this study will be pseudo-anonymised and kept securely at The Christie, only accessible to those employed by the Christie NHS Foundation Trust. Due to the data not being fully anonymised and to preserve patient confidentiality the data from this study will not be shared.
Related trials for Metastatic Spinal Cord Compression
Active, not recruitingPhase 1
Phase I Study of Feasibility of Single Session Spine Stereotactic Radiosurgery (SSRS) in the Primary Management in Patients With Inoperable, Previously Unirradiated Metastatic Epidural Spinal Cord Compression (MESCC)
Metastatic Epidural Spinal Cord Compression
Active, not recruitingPhase 2
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma
RecruitingPhase 2
Risk Adapted Spinal Cord/Cauda Constraint Relaxation for High-risk Patients With Metastatic Epidural Spinal Cord Compression Undergoing Spine Stereotactic Radiosurgery
Spinal Cord, Metastatic Epidural
RecruitingObservational study
Postoperative Edge (RapidArc) Stereotactic Body Radiotherapy for Spinal Metastases
Spinal Metastases, Metastatic Epidural Spinal Cord Compression
Not yet recruiting
Miami "RADAR" Trial
Metastatic Epidural Spinal Cord Compression, Spinal Cord Compression
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Cynthia L Eccles principal investigator
The Christie NHS Foundation Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Radiotherapy to the spine in a single appointment in people with Metastatic Spinal Cord Compression, run by The Christie NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clinical Trial Radiographer (+441614468386, the-christie.radiotherapyclinicaltrials@nhs.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Successful treatment of Metastatic Spinal Cord Compression in a single 1 hour appointment for 80% of patients on the MRL Arm (time frame: The event is assessed on a single day (within 24hours) over a single appointment. From the time the patient enters the treatment room to the time the radiotherapy beam is completed (Up to 2 hours in length).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06965101, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2025.